The US Food and Drug Administration will likely want sponsors to pivot from placebo-controlled trials to studies with active comparators once there is adequate supply of highly efficacious COVID-19 vaccines, Center for Biologics Evaluation and Research Director Peter Marks said.
“It would not be ethical at that point,” Marks said in an interview at the FDA-CMS Summit on 7 December.







